NCT04369937 - "HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for Intermediate Risk HPV-16-associated Head and Neck Squamous Cell Carcinoma" | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

March 12, 2025

Study Completion Date

January 15, 2026

Conditions

HPV-Related Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma

Interventions

RADIATION

IMRT (Intensity Modulated Radiotherapy)

Radiation therapy

DRUG

Pembrolizumab

A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.

DRUG

Cisplatin

Chemotherapy

BIOLOGICAL

ISA101b

ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh